Souhaitez-vous accéder aux communiqués récents ?

Announced strategic collaboration with Mayo Clinic, focused on improving care in type 1 diabetes and accelerating development of SC451 Continued progress toward starting SC451 Phase 1 trial later...

-- On track to file IND and/or CTA for PM577 in Wilson Disease in H1 2026 and for PM647 in AATD mid-2026; initial clinical data from both programs expected in 2027 -- -- Continued regulatory dialogue...

Company announcement – No. 14 / 2026 Zealand Pharma Announces Financial Results for the First Three Months of 2026 A defining start to 2026, marked by pivotal progress for leading obesity assets,...

Dublin, April 20, 2026 (GLOBE NEWSWIRE) -- The "Liabilities, Damages and other Contentious Issues in International Commercial Agreements (July 16th - July 17th, 2026)" has been added to ...

CAMBRIDGE, Mass., April 16, 2026 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic...

Dublin, April 15, 2026 (GLOBE NEWSWIRE) -- The "Influence, Lead, Persuade and Negotiate: A Workshop for Driving Results in Legal Practice (Apr 20th - Apr 22nd, 2026)" training has been added to ...

Sana and Mayo Clinic to collaborate across multiple areas with goal of accelerating development of and access to potentially curative therapies for patients with type 1 diabetes Initial efforts will...

Dublin, April 13, 2026 (GLOBE NEWSWIRE) -- The "Practical Business and Contract Law for Commercial Professionals (May 7th - May 8th, 2026)" training has been added to ResearchAndMarkets.com's...

Dublin, April 10, 2026 (GLOBE NEWSWIRE) -- The "The Annual International Commercial Contracts Executive School (June 4th - June 11th, 2026)" training has been added to ResearchAndMarkets.com's...

CAMBRIDGE, Mass., April 01, 2026 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease,...